Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or unknown locally advanced, or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following anti-estrogen therapy.
Assess & initiate treatment for bone mineral density of women w/ or at risk of osteoporosis. Patients w/ CrCl <10 mL/min. Not for use in men w/ breast cancer. Hepatic &/or renal impairment. Not recommended for childn.